Study type

Study type

Non-interventional study

Scope of the study

Assessment of risk minimisation measure implementation or effectiveness
Drug utilisation
Effectiveness study (incl. comparative)
Non-interventional study

Non-interventional study design

Cohort
Study drug and medical condition

Name of medicine, other

Corticosteroids, Interleucin inhibitors, JAK inhibitors, Statins, Anti-diabetics, Protease inhibitors, Anticoagulants

Study drug International non-proprietary name (INN) or common name

HYDROXYCHLOROQUINE

Anatomical Therapeutic Chemical (ATC) code

(C02) ANTIHYPERTENSIVES
ANTIHYPERTENSIVES
(J02AA) Antibiotics
Antibiotics

Medical condition to be studied

COVID-19 treatment
Population studied

Age groups

Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Estimated number of subjects

2500000
Study design details

Main study objective

Specifically, the study has the following objectives:1. To assess comparative effectiveness and safety among treatments administered during hospitalization and prior to intensive services2. To assess comparative effectiveness and safety among treatments administered after COVID-19 positive testing or diagnosis in outpatient setting without prior hospitalization

Data analysis plan

One study design, with multiple different analysis variants, will be conducted after appropriate diagnostics to rule out power and/or confounding issues. For each research question in section 8, we have identified treatments that 1) have in vitro antiviral activity for SARS-COV-2 virus, or 2) are considered concomitant therapies for the COVID-19 disease. The latter are subdivided into antithrombotics, antibiotics, immune-based therapies, concomitant anti-hypertensive, concomitant anti-diabetics, concomitant statin, and other concomitant treatments (see Appendix 1). For each question, we will make pairwise comparisons of all treatments within these eight categories of therapies (e.g. compare all drugs with antiviral activity against each other, and separately compare all antithrombotic therapies with each other). For each comparison, we will estimate and compare the incidences of each outcome in Appendix 2 during the time-at-risk windows defined in 9.2.3.